We evaluated the clinical effects of lamivudine treatment in liver cirrhosis. Five cirrhotic patients with hepatitis B virus infection were treated with lamivudine. Comparison between the data at start of treatment and after 9 months of treatment showed improvement in liver function tests. They are a decrease in serum total bilirubin from 0.7-6.2 (median 3.1) to 0.8-3.1 (median 0.8) mg/dl, a decrease in ALT from 50-268 (median 74) to 19-44 (median 30) IU/l, a decrease in TTT from 20.1-33.1 (median 29.9) to 5.5-19.8 (median 14.3) Kunkel, an increase in serum albumin from 3.1-4.8 (median 3.5) to 3.1-5.1 (median 3.9) g/dl, an increase in cholinesterase from 79-211 (median 94) to 118-315 (median 206) IU/l, and a decrease in HBV DNA from 108.00-108.92 (median 108.32) to < 102.00-105.30 (median < 102.00) copies/ml. It was shown that lamivudine treatment for cirrhotic patients with hepatitis B virus infection has improved not only hepatic inflammation but also protein synthetic function of liver.
ASJC Scopus subject areas